ZNTL · NASDAQ · Biotechnology

Zentalis Pharmaceuticals (ZNTL)

Develops azenosertib for biomarker-selected platinum-resistant ovarian cancer.

$3.84
Pre-market+0.06 (+1.59%)
At close$3.78(+1.89%)

Something off on this page? Send us feedback.

Next report
Nov 10, 2026
estimated · in 68 days
EPS estimate
−$0.61
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.67−$0.37−$0.37−$0.49−$0.50−$0.59−$0.59Pending
Estimate−$0.67−$0.56−$0.49−$0.41−$0.49−$0.45−$0.49−$0.61
Surprise0.0%+33.9%+24.5%−19.5%−2.0%−31.1%−20.4%

RevenueReportedEstimate

May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.61
Aug 2026−$0.49−$0.59−20.4%
Aug 2026−$0.45−$0.59−31.1%
May 2026−$0.49−$0.50−2.0%
Mar 2026−$0.41−$0.49−19.5%

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
Nov 2025
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Feb 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Apr 2020
Sep 2019
Jun 2019
Mar 2019
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 10, 2026−$0.61
Aug 6, 2026−$0.49−$0.59−20.4%−15.6%
Aug 5, 2026−$0.45−$0.59−31.1%+1.0%
May 12, 2026−$0.49−$0.50−2.0%0.0%
Mar 26, 2026−$0.41−$0.49−19.5%−21.4%

The latest year is open to everyone — the 27 quarters behind it read with an account.

Sign in
Nov 10, 2025
Aug 6, 2025
May 14, 2025
Mar 26, 2025
Nov 12, 2024
Aug 9, 2024
May 7, 2024
Feb 27, 2024
Nov 6, 2023
Aug 9, 2023
May 10, 2023
Mar 1, 2023
Nov 9, 2022
Aug 9, 2022
May 5, 2022
Feb 24, 2022
Nov 10, 2021
Aug 12, 2021
May 17, 2021
Mar 25, 2021
Nov 9, 2020
Aug 13, 2020
May 15, 2020
Apr 6, 2020
Sep 30, 2019
Jun 30, 2019
Mar 31, 2019